Literature DB >> 19434559

Neurobiology and systems physiology of the endocannabinoid system.

N Wegener1, M Koch.   

Abstract

Endocannabinoids are synthesised from lipid precursors, are released from postsynaptic neurons in an activity-dependent way, and act as retrograde signalling messengers on specific G (i)-protein-coupled cannabinoid (CB (1)) receptors on presynaptic terminals. Hence, endocannabinoids are in a strategic position to regulate transmitter release. CB (1)-receptors are abundant on GABAergic, glutamatergic and dopaminergic synapses and play an essential role in a variety of cognitive processes and in the control of behaviour. The endocannabinoid system is not only the target of the psychoactive components of the hemp plant (tetrahydrocannabinol from hashish and marijuana) but has also been exploited for drugs acting as agonists (e.g. dronabinol) or antagonists (e.g. rimonabant) of the CB (1)-receptor. The former drugs exert orexigenic effects and can be used for the mitigation of anorexia e.g. in cancer patients, but have also been used for the treatment of multiple sclerosis. The latter have been used to treat adipositas. The role of the endocannabinoid system in the development of drug dependence has been discussed controversially, but recent evidence suggests that chronic stimulation of the endocannabinoid system may facilitate drug dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19434559     DOI: 10.1055/s-0029-1216346

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  6 in total

1.  Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.

Authors:  Verena Isabell Leussink; Leila Husseini; Clemens Warnke; Erasmia Broussalis; Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2012-09       Impact factor: 6.570

Review 2.  [Cannabinoids for symptomatic therapy of multiple sclerosis].

Authors:  L Husseini; V I Leussink; C Warnke; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

3.  Mechanisms Underlying Sex Differences in Cannabis Use.

Authors:  Katina C Calakos; Shivani Bhatt; Dawn W Foster; Kelly P Cosgrove
Journal:  Curr Addict Rep       Date:  2017-10-19

4.  Excitability decreasing central motor plasticity is retained in multiple sclerosis patients.

Authors:  Daniel Zeller; Su-Yin Dang; David Weise; Peter Rieckmann; Klaus V Toyka; Joseph Classen
Journal:  BMC Neurol       Date:  2012-09-13       Impact factor: 2.474

Review 5.  Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.

Authors:  Sebastian Walther; Michael Halpern
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-17

6.  Cannabinoids: well-suited candidates for the treatment of perinatal brain injury.

Authors:  David Fernández-López; Ignacio Lizasoain; Maria Angeles Moro; José Martínez-Orgado
Journal:  Brain Sci       Date:  2013-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.